Difference between revisions of "Fenelzine-tranylcypromine"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = tranylcypromine | | to = tranylcypromine | ||
| stop = | | stop = | ||
| + | 15 mg fenelzine per twee weken | ||
{{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref> | {{14dWashout}}<ref>van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.</ref> | ||
Revision as of 16:29, 14 April 2026
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Switch medication from fenelzine to tranylcypromine[1][2]
Stop fenelzine 15 mg fenelzine per twee weken
- Stop and wait 14 days for washout[3]
Start tranylcypromine- Start tranylcypromine in a low dosage of 20 mg/day for one week.
- After this week the dosage of tranylcypromine can be increased.
Cave- Occurrence of the serotonin syndrome is possible without wash-out period.
- Tranylcypromine and fenelzine are irreversible MAO inhibitors for MAO-A and MAO-B. Fenelzine has higher affinity for MAO-A, whereas tranylcypromine has higher affinity for MAO-B. Side effects could occur during a switch. In addition, monitoring of sodium levels is adviced.[4]
- Known side effect for tranylcypromine are sleeping problems, agitation and orthostatic hypotension.
- Known side effects in fenelzine are oedema and/or increased liver enzyme levels.
- It is adviced to admit the patient in a mental health care clinic for intensive monitoring during this switch.[5]
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ van den Eynde et al. The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression CNS Spectr 2023;28(4):427-440. doi: 10.1017/S1092852922000906.
- ↑ A van Diepen et al. De lange mars van farma naar patiënt Medisch Contact May 2021
- ↑ van den Eynde et al. Richtlijn voor het gebruik van klassieke MAO-remmers Psyfar 2023 nr 2
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
